Background:
- Human immunodeficiency virus (HIV)-infected patients have a weakened immune system,
and chemotherapy, which is used to treat lymphoma, probably causes further damage to
the immune system.
- Limiting the amount of immune damage due to chemotherapy might decrease the number
of infections and the risk of developing cancer in the future in HIV-infected
patients with non-Hodgkin's lymphoma.
Objectives:
- To determine whether reducing the total amount of chemotherapy using a specific
combination of drugs called EPOCH-R (etoposide, doxorubicin, vincristine,
cyclophosphamide and rituximab) will rid the body of lymphoma quickly while
decreasing the risk of infections and future cancers.
- To determine whether the lymphoma will remain undetectable for at least one year if
treatment is stopped one cycle after the patient enters remission.
Eligibility:
-Patients with non-Hodgkin's lymphoma and HIV infection 4 years of age and older who have
not been treated previously with rituximab or cytotoxic chemotherapy.
Design:
- Patients receive EPOCH-R in 3-week treatment cycles for at least three and no more
than six cycles.
- The lymphoma is evaluated using computed tomography (CT) and positron emission
tomography (PET) scans at the end of treatment cycles 2 and 3. A bone marrow biopsy
is repeated after cycle 2 if a biopsy was initially positive on screening for
participation in the study.
- Anti-HIV therapy is stopped before chemotherapy begins and is restarted when EPOCH-R
treatment ends.
- Patients are monitored for treatment response with blood tests and imaging scans at
baseline, when treatment ends, 2 months after treatment ends and then every 3 to 6
months for a total of 24 months following chemotherapy.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT00006436.
Background:
This is a study to investigate in a preliminary fashion the feasibility of short course
chemotherapy to participants with HIV-associated non-Hodgkin's lymphoma (HIV-NHL).
This study will investigate if the paradigm for treatment can be successfully changed
from a standard of 6 cycles to one cycle beyond complete remission with 6 total allowable
cycles.
Objective:
To assess with 90 percent probability that at least 50 percent of participants treated
with short-course EPOCH-R (etoposide, doxorubicin, vincristine, cyclophosphamide and
rituximab) will be progression free at one year.
Eligibility:
Aggressive B-lymphocyte antigen CD20 (CD20) positive Diffuse large B cell lymphoma
(DLBCL).
HIV+ serology.
All stages (I-IV) of disease.
Eastern Cooperative Oncology Group (ECOG) Performance status 0-4.
Non-Hodgkin's Lymphoma (NHL) previously untreated with cytotoxic chemotherapy.
Age greater than or equal to 18 years.
May not be pregnant or nursing.
May not have received previous rituximab.
Design:
Participants will be treated every three weeks with a combination of EPOCH and rituximab
for one cycle beyond complete remission (CR)/complete response unconfirmed (CRu) by
computed tomography (CT) scan of all detectable tumors for a minimum of three and maximum
of six cycles. Following cycle 2, CT, positron emission tomography scans (PET), and bone
marrow biopsies (if initially positive) will be performed.
At the conclusion of the study, we will estimate whether the number of cycles can be
reduced using the paradigm. If the cumulative number of participants to relapse exceeds
25 percent by 6 months, the study will be closed.
Following the completion of chemotherapy, restaging will be performed 2 months following
the end of treatment, then every 3 months for one year, every 6 months for one year, then
every 12 months until relapse, death, or loss to follow up.
Antiretroviral therapy (ART) will be given concurrently with treatment regimen.
To study the effects of treatment approach on parameters of HIV disease, measurements of
cluster of differentiation 4 (CD4) cells and viral loads will be made at baseline and at
the completion of therapy, and then 2 months following the end of treatment, and then
every 3-6 months for a total of 24 months following chemotherapy.
Lead OrganizationNational Cancer Institute
Principal InvestigatorMark Jason Roschewski
